• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How TRYNGOLZA Approval and New Equity Shelf At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story

    Simply Wall St·08/10/2026 11:22:31
    Listen to the news
    • Ionis Pharmaceuticals recently secured FDA approval for TRYNGOLZA, the first medicine to lower triglycerides and reduce acute pancreatitis risk in adults with severe hypertriglyceridemia, while also reporting weaker second-quarter results and filing a US$546.12 million shelf registration for 10,250,000 common shares tied to an ESOP offering.
    • At the same time, Ionis is transitioning its leadership in research as long-time chief scientific officer Frank Bennett prepares for retirement, while the company leans on expanding commercial launches such as TRYNGOLZA, DAWNZERA and the anticipated Zilganersen rollout to support its 2026 revenue guidance of US$875 million to US$900 million.
    • Now we’ll examine how the TRYNGOLZA approval, expanding Ionis’ severe hypertriglyceridemia reach, could reshape the company’s investment narrative.

    Find 52 companies with promising cash flow potential yet trading below their fair value.

    Ionis Pharmaceuticals Investment Narrative Recap

    To own Ionis, you have to believe its RNA medicines can convert a focused rare-disease portfolio into a broader, sustainable commercial franchise. The TRYNGOLZA approval in severe hypertriglyceridemia strengthens that case as a near term growth driver, but the weaker second quarter and ongoing net losses keep execution and pricing risk front and center. The biggest near term swing factor remains how quickly new launches can offset lumpy revenues and pressure on margins.

    Among the recent updates, the new 2026 revenue guidance of US$875 million to US$900 million is most relevant. It frames how management expects TRYNGOLZA, DAWNZERA and a potential Zilganersen launch to build a more commercial weighted revenue mix, even as the company absorbs pricing pressures, partner variability and higher launch costs in the next couple of years.

    Yet, behind this growth story, investors should be aware that pricing pressure and broader sHTG exposure could still...

    Read the full narrative on Ionis Pharmaceuticals (it's free!)

    Ionis Pharmaceuticals' narrative projects $2.2 billion revenue and $212.1 million earnings by 2029.

    Uncover how Ionis Pharmaceuticals' forecasts yield a $92.00 fair value, a 63% upside to its current price.

    Exploring Other Perspectives

    IONS 1-Year Stock Price Chart
    IONS 1-Year Stock Price Chart

    Some of the lowest estimate analysts were already assuming only about 23% annual revenue growth to roughly US$2.0 billion by 2029, which is far more cautious than the consensus story and the TRYNGOLZA driven upside many investors focus on today.

    Explore 3 other fair value estimates on Ionis Pharmaceuticals - why the stock might be worth just $79.71!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free Ionis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.

    Ready To Venture Into Other Investment Styles?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.